Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
Shiting Xu(Juntendo University), Kazuhisa Takahashi(Kansai Medical University), Keita Miura(Juntendo University), Jun Tamura(Yokohama City University), Kana Kurokawa(Juntendo University), Tetsuhiko Asao(Cornell University), Daisuke Hayakawa(Juntendo University), Kouji Yamamoto(Yokohama City University), Shoko Shimamura(Japanese Foundation For Cancer Research), Taichi Miyawaki(Juntendo University), Takehito Shukuya(Juntendo University)
Cited by 36
Related Papers
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
|Journal of Clinical Oncology|2019|483
Leveraging fine-mapping and multipopulation training data to improve cross-population polygenic risk scores
|Nature Genetics|2022|279
Confidence interval for micro-averaged F1 and macro-averaged F1 scores
|Applied Intelligence|2021|273